Physicians' Academy for Cardiovascular Education

Intermittent energy restricted diet results in comparable HbA1c reduction as continuous restricted diet in obese diabetic patients

Effect of Intermittent Compared With Continuous Energy Restricted Diet on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Noninferiority Trial

Literature - Carter S, Clifton PM, Keogh JB. - JAMA Network Open 2018;1(3):e180756

Introduction and methods

Short periods of severe energy restriction followed by longer periods of habitual eating, or alternate-day modified fasting (intermittent energy restrictions, IER) lead to weight loss equivalent to continuous energy restriction (CER) (3-5 kg within 10 weeks) [1-3], but there are limited data on whether IER has a beneficial impact on glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2DM).

This randomized non-inferiority trial evaluated the long-term effects of an IER diet compared with a CER diet during a 12-month period in T2DM patients. For this purpose, patients with T2DM, aged ≥18years, and a body mass index (BMI) ≥27 kg/m2 were randomized 1:1 to IER (n=70) or CER (n=67) between 2015 and 2017. The IER consisted of a 500-600 kcal/day diet (including a minimum of 50 g of protein per day) for two days of the week, followed by usual diet for the other five days of the week. The CER consisted of a 1,200-1,500 kcal/day diet (30% protein, 45% carbohydrate, and 25% fat).

Sulfonylureas and insulin were discontinued permanently if HbA1c <7%, or discontinued on IER days only if HbA1c 7-10%, or remained unchanged if HbA1c was >10%. The primary outcome was change in HbA1c level and the secondary outcome was change in body weight. Exploratory outcomes included daily step count, body composition, measured by dual-energy x-ray absorptiometry, fasting glucose and serum lipid levels.

Main results

Conclusion

In adult overweight and obese T2DM patients, an IER diet led to equivalent HbA1c reductions compared with a CER diet. An IER diet is acceptable for most T2DM patients and safe for those who do not use hypoglycemic agents. For patients receiving sulfonylureas and/or insulin, regular monitoring of blood glucose levels remains important.

References

Show references

Download the slide Find this article online at JAMA Network Open